Spain Onychomycosis Market Size & Outlook, 2025-2033
Related Markets
Spain onychomycosis market highlights
- The Spain onychomycosis market generated a revenue of USD 73.4 million in 2024 and is expected to reach USD 107.4 million by 2033.
- The Spain market is expected to grow at a CAGR of 4.4% from 2025 to 2033.
- In terms of segment, topical was the largest revenue generating treatment in 2024.
- Topical is the most lucrative treatment segment registering the fastest growth during the forecast period.
Onychomycosis market data book summary
| Market revenue in 2024 | USD 73.4 million |
| Market revenue in 2033 | USD 107.4 million |
| Growth rate | 4.4% (CAGR from 2025 to 2033) |
| Largest segment | Topical |
| Fastest growing segment | Topical |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Oral, Topical |
| Key market players worldwide | GSK PLC, Abbott Laboratories, Pfizer Inc, Bausch Health Companies Inc, Bayer AG, Teva Pharmaceutical Industries Ltd, Cipla Ltd DR, Merck & Co Inc, Novartis AG ADR, Sun Pharmaceutical Industries |
Other key industry trends
- In terms of revenue, Spain accounted for 1.9% of the global onychomycosis market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany onychomycosis market is projected to lead the regional market in terms of revenue in 2033.
- Italy is the fastest growing regional market in Europe and is projected to reach USD 203.1 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Onychomycosis Market Scope
Onychomycosis Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Bausch Health Companies Inc | View profile | 20270 | 2150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8 | https://www.bauschhealth.com |
| Sun Pharmaceutical Industries | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | http://www.sunpharma.com |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Cipla Ltd DR | View profile | 38955 | Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, India, 400 013 | https://www.cipla.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Spain onychomycosis market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to onychomycosis market will help companies and investors design strategic landscapes.
Topical was the largest segment with a revenue share of 36.92% in 2024. Horizon Databook has segmented the Spain onychomycosis market based on oral, topical covering the revenue growth of each sub-segment from 2021 to 2033.
The market is becoming increasingly lucrative for onychomycosis drugs, creating opportunities for market players. The products used for treating nail fungus are expected to receive approvals from national and regional government authorities.
For instance, MOB-015, a topical formulation by Moberg Pharma AB, is suggested for national approval in 13 European nations for treating fungal infections of the nails in adults. These 13 countries also include Spain, along with other European nations.
Such recommendations and approvals are expected to drive the market competition over the forecast period. Furthermore, the rising incidence of HIV is expected to boost the demand for onychomycosis drugs and medicines, as onychomycosis can be observed in patients suffering from HIV infection.
Reasons to subscribe to Spain onychomycosis market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Spain onychomycosis market databook
-
Our clientele includes a mix of onychomycosis market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain onychomycosis market , including forecasts for subscribers. This country databook contains high-level insights into Spain onychomycosis market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Spain onychomycosis market size, by treatment, 2021-2033 (US$M)
Spain Onychomycosis Market Outlook Share, 2024 & 2033 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
